Virulence of Mycobacterium intracellulare clinical strains in a mouse model of lung infection - role of neutrophilic inflammation in disease severity.
Chemotherapeutic efficacy
Mycobacterium intracellulare
Neutrophil
Nontuberculous mycobacteria
Virulence
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
03 04 2023
03 04 2023
Historique:
received:
07
12
2022
accepted:
21
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Mycobacterium intracellulare is a major etiological agent of Mycobacterium avium-intracellulare pulmonary disease (MAC-PD). However, the characteristics of the virulence of M. intracellulare and the in vivo chemotherapeutic efficacy remain unclear. In this study, we examined the virulence of nine M. intracellulare strains with different clinical phenotypes and genotypes in C57BL/6 mice. We classified three types of virulence phenotypes (high, intermediate, and low) based on the kinetics of the bacterial load, histological lung inflammation, and neutrophilic infiltration. High virulence strains showed more severe neutrophilic infiltration in the lungs than intermediate and low virulence strains, with 6.27-fold and 11.0-fold differences of the average percentage of neutrophils in bronchoalveolar lavage fluid, respectively. In particular, the high virulence strain M.i.198 showed the highest mortality in mice, which corresponded to the rapid progression of clinical disease. In mice infected with the drug-sensitive high virulence strain M019, clarithromycin-containing chemotherapy showed the highest efficacy. Monotherapy with rifampicin exacerbated lung inflammation with increased lymphocytic and neutrophilic infiltration into the lungs. The virulence phenotypes of clinical strains of M. intracellulare were diverse, with high virulence strains being associated with neutrophilic infiltration and disease progression in infected mice. These high virulence strains were proposed as a useful subject for in vivo chemotherapeutic experiments.
Sections du résumé
BACKGROUND
Mycobacterium intracellulare is a major etiological agent of Mycobacterium avium-intracellulare pulmonary disease (MAC-PD). However, the characteristics of the virulence of M. intracellulare and the in vivo chemotherapeutic efficacy remain unclear. In this study, we examined the virulence of nine M. intracellulare strains with different clinical phenotypes and genotypes in C57BL/6 mice.
RESULTS
We classified three types of virulence phenotypes (high, intermediate, and low) based on the kinetics of the bacterial load, histological lung inflammation, and neutrophilic infiltration. High virulence strains showed more severe neutrophilic infiltration in the lungs than intermediate and low virulence strains, with 6.27-fold and 11.0-fold differences of the average percentage of neutrophils in bronchoalveolar lavage fluid, respectively. In particular, the high virulence strain M.i.198 showed the highest mortality in mice, which corresponded to the rapid progression of clinical disease. In mice infected with the drug-sensitive high virulence strain M019, clarithromycin-containing chemotherapy showed the highest efficacy. Monotherapy with rifampicin exacerbated lung inflammation with increased lymphocytic and neutrophilic infiltration into the lungs.
CONCLUSIONS
The virulence phenotypes of clinical strains of M. intracellulare were diverse, with high virulence strains being associated with neutrophilic infiltration and disease progression in infected mice. These high virulence strains were proposed as a useful subject for in vivo chemotherapeutic experiments.
Identifiants
pubmed: 37009882
doi: 10.1186/s12866-023-02831-y
pii: 10.1186/s12866-023-02831-y
pmc: PMC10069106
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
94Informations de copyright
© 2023. The Author(s).
Références
J Clin Microbiol. 2005 Jul;43(7):3150-8
pubmed: 16000428
Antimicrob Agents Chemother. 1987 Nov;31(11):1697-702
pubmed: 3124736
Sci Rep. 2017 Jan 03;7:39750
pubmed: 28045086
J Clin Invest. 2007 Jul;117(7):1738-45
pubmed: 17607348
BMC Infect Dis. 2014 Feb 28;14:114
pubmed: 24576098
Front Immunol. 2021 Oct 05;12:712457
pubmed: 34675916
J Clin Invest. 2005 Sep;115(9):2480-8
pubmed: 16127458
Clin Exp Immunol. 1994 Nov;98(2):210-6
pubmed: 7955524
Lancet. 2004 Dec 11-17;364(9451):2113-21
pubmed: 15589309
J Infect Dis. 2008 Jun 1;197(11):1506-10
pubmed: 18422455
BMC Clin Pathol. 2003 Sep 12;3(1):3
pubmed: 12971830
Antimicrob Agents Chemother. 2015 Apr;59(4):2129-35
pubmed: 25624335
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
J Clin Invest. 2020 Jun 1;130(6):3113-3123
pubmed: 32125282
J Infect Dis. 2021 Jun 15;223(12):2124-2135
pubmed: 33104218
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32071046
Mucosal Immunol. 2021 Jan;14(1):229-241
pubmed: 32483198
J Clin Microbiol. 2005 Sep;43(9):4407-12
pubmed: 16145084
Respir Investig. 2018 Jan;56(1):87-93
pubmed: 29325687
Am J Respir Cell Mol Biol. 1990 Aug;3(2):131-5
pubmed: 2378747
Microb Pathog. 2009 Jan;46(1):6-12
pubmed: 19013228
J Immunol. 2004 Mar 1;172(5):2731-8
pubmed: 14978070
Emerg Infect Dis. 2016 Jun;22(6):1116-7
pubmed: 27191735
N Engl J Med. 1996 Dec 26;335(26):1941-9
pubmed: 8960473
Eur Respir J. 2020 Jul 7;56(1):
pubmed: 32636299
Am J Respir Crit Care Med. 2012 Apr 15;185(8):881-6
pubmed: 22312016
PLoS One. 2018 Feb 5;13(2):e0190189
pubmed: 29401501
J Clin Microbiol. 1990 Jun;28(6):1105-7
pubmed: 2380348
Am J Respir Crit Care Med. 1999 Dec;160(6):1851-5
pubmed: 10588596
J Immunol. 2007 Jun 15;178(12):8028-35
pubmed: 17548640
Infect Genet Evol. 2014 Jan;21:375-83
pubmed: 24345519
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Chest. 2010 Jan;137(1):122-8
pubmed: 19749004
Eur Respir J. 2013 Dec;42(6):1750-2
pubmed: 24293422
J Immunol. 2005 Oct 1;175(7):4769-76
pubmed: 16177125
BMC Microbiol. 2021 Apr 6;21(1):103
pubmed: 33823816
Int Immunol. 2010 Mar;22(3):179-89
pubmed: 20139174
Respir Med Case Rep. 2017 Feb 28;20:201-204
pubmed: 28331797
Microbiol Spectr. 2022 Jun 29;10(3):e0053022
pubmed: 35467367
Int J Tuberc Lung Dis. 2007 Dec;11(12):1290-5
pubmed: 18034948
J Exp Med. 1992 Apr 1;175(4):1111-22
pubmed: 1552282
Clin Microbiol Rev. 2003 Jul;16(3):463-96
pubmed: 12857778
Sci Rep. 2021 Sep 9;11(1):18008
pubmed: 34504192
PLoS Pathog. 2016 May 31;12(5):e1005667
pubmed: 27244558
Science. 2006 Mar 24;311(5768):1770-3
pubmed: 16497887
J Clin Med. 2020 May 02;9(5):
pubmed: 32370226
Immunity. 2021 Sep 14;54(9):2143-2158.e15
pubmed: 34453881
Sci Rep. 2020 Mar 25;10(1):5449
pubmed: 32214196
Eur Respir J. 2021 Aug 12;58(2):
pubmed: 33542050
BMC Infect Dis. 2019 Dec 16;19(1):1055
pubmed: 31842775
Science. 2001 Feb 23;291(5508):1544-7
pubmed: 11222859